Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 9/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11138422 | 0.86 | HTR2C (0.43) | KDM1AHTR2CMAOBALDH1A1 | |
| SCHEMBL29748038 | 0.86 | HTR2C (0.43) | KDM1AHTR2CMAOBALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL14829349 | 0.82 | KDM1A (0.44) | KDM1ACTSK | |
| Trifluoroacetic Acid SCHEMBL14830108 | 0.81 | SLC6A2 (0.41) | KDM1A | |
| Trifluoroacetic Acid SCHEMBL14839831 | 0.79 | KDM1A (0.47) | KDM1ACTSKKDM4EMAPT | |
| Trifluoroacetic Acid SCHEMBL14829254 | 0.79 | PRCP (0.34) | PRCPKDM1ACTSKSSTR4 | |
| SCHEMBL29747706 | 0.78 | HTR2C (0.41) | KDM1AHTR2C | |
| Trifluoroacetic Acid SCHEMBL14839956 | 0.76 | SSTR4 (0.37) | KDM1ASSTR4TRPV1 | |
| Trifluoroacetic Acid SCHEMBL14829650 | 0.75 | KCNH2 (0.43) | KDM1ACTSKHPGD | |
| Trifluoroacetic Acid SCHEMBL14837280 | 0.75 | KDM1A (0.47) | KDM1ACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751088-B1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2016-04-13 | — | — | EP | disclosed |
| US-8765751-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130089624-A1 | Compounds Useful as Inhibitors of ATR Kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089624-A1 | Compounds Useful as Inhibitors of ATR Kinase | ATR, CHEK1, PLK1 | PRCP 2674/4885KDM1A 2426/4885HTR2C 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.